Ayvakit (avapritinib) — Medica
Gastrointestinal stromal tumor (GIST)
Preferred products
- imatinib
- sunitinib
- Sprycel (dasatinib)
- Stivarga (regorafenib)
- Qinlock (ripretinib)
Initial criteria
- Patient is age ≥ 18 years
- EITHER the tumor is positive for platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation (including PDGFRA D842V) OR patient has tried ALL of the following: imatinib, ONE of sunitinib or Sprycel (dasatinib), Stivarga (regorafenib), and Qinlock (ripretinib)
Approval duration
1 year